Doximity Soars After Q1 Revenue Tops Guidance; Raises FY2027 View
Doximity (DOCS) reported Q1 FY2027 revenue of $156.62M, up 7% and above its prior guidance range of $151M to $152M. Net income fell to $24.32M ($0.13/share) from $53.32M ($0.27). For Q2, it expects revenue of $170M to $171M and adjusted EBITDA of $80.5M to $81.5M. FY2027 revenue guidance was raised to $671M to $681M.
How this was made
The 30-second read
Why it matters
Q1 revenue beat and raised FY2027 revenue guidance are the core catalysts, while the lower net income and slightly lower adjusted EBITDA outlook add execution risk.
Market read
Guidance raises after a Q1 beat can drive rapid repricing, especially given the large reported post-news rally.
What to watch
Adjusted EBITDA guidance is widened and slightly reduced versus the prior range, so traders should watch whether revenue growth can translate into margin expansion.
Background
DOCS is a digital platform for medical professionals and is highlighting its clinical AI assistant, Doximity Ask.
Ticker impact
Doximity (DOCS) reported Q1 FY2027 revenue above guidance and raised FY2027 revenue and adjusted EBITDA outlook.
Bullish bias for DOCS, with follow-through risk if the raised EBITDA range proves conservative.
The article discloses specific Q1 results versus guided range and provides updated FY2027 revenue and adjusted EBITDA ranges, which are direct drivers for earnings expectations.
Market effects
Strength in a healthcare IT platform can lift sentiment toward digital health and clinical AI adoption narratives.
Primarily US small/mid-cap growth sentiment, with limited direct regional spillover described.
No explicit global demand, partnerships, or regulatory changes mentioned.
Counterpoint
The stock’s move may be overstated because net income fell year over year and the full-year adjusted EBITDA range is only slightly lower than the prior midpoint.
Key entities
- companyDoximity, Inc.
Reported Q1 FY2027 results above guidance and raised FY2027 revenue and updated adjusted EBITDA forecast.
- productDoximity Ask
Clinical AI assistant recognized as top-performing U.S.-based model in the NOHARM benchmark.
